Harnessing a cRGD-Targeted Schottky Junction MXene Nanocomposite for Potent Bladder Cancer Therapy: Dual-Modal PTT/PDT Effects with Immune Activation and Favorable Comparison to Doxorubicin
Zhibo Gu, Hua Zhu, Yong Zhang, Jie Jiang, Donghua Gu, Jiangang Chen · 2026
Read Harnessing a cRGD-Targeted Schottky Junction MXene Nanocomposite for Potent Bladder Cancer Therapy: Dual-Modal PTT/PDT Effects with Immune Activation and Favorable Comparison to Doxorubicin by Zhibo Gu, Hua Zhu, Yong Zhang, Jie Jiang, Donghua Gu, Jiangang Chen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13271140.txt.
Description
Zhibo Gu and co-authors build a light driven nano drug for bladder cancer in a 2026 study. Their mix sets iron manganese oxide bits on MXene sheets, forming a Schottky junction that turns near infrared light into heat and reactive oxygen. A ring peptide coat steers the mix toward tumor cells.
Lab checks confirmed clean build, stable spread in fluid, broad light uptake, and strong heat and oxygen yields under laser light. Cancer cells in dishes took the mix in well. A mouse bladder tumor model then gauged kill power, and body safety checks ran beside it. The team set results against the standard drug doxorubicin as a bench mark.
Catalog record
| CREATOR | Zhibo Gu, Hua Zhu, Yong Zhang, Jie Jiang, Donghua Gu, Jiangang Chen |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 72 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |